Development of multicentric hepatocellular carcinoma after completion of interferon therapy
暂无分享,去创建一个
M. Kudo | M. Hirai | Y. Yano | Y. Hayashi | K. Ando | S. Kim | Y. Maekawa | T. Ninomiya | S. Imoto | Ketherine Kim | K. Mita | T. Matsuoka | M. Nakaji | K. Fukuda | S. Shintani | T. Koterazawa | H. Ikawa
[1] Valeer J Desmet,et al. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. , 2003, Journal of hepatology.
[2] A. Oshima,et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients , 2000, International journal of cancer.
[3] Y. Liaw,et al. Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis , 2000, Hepatology.
[4] Yasuyuki Arakawa,et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan , 1999, Annals of Internal Medicine.
[5] K. Shimotohno,et al. Hepatitis C Virus Core Protein Inhibits Fas- and Tumor Necrosis Factor Alpha-Mediated Apoptosis via NF-κB Activation , 1999, Journal of Virology.
[6] Yoshiharu Matsuura,et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice , 1998, Nature Medicine.
[7] N. Hayashi,et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C , 1998, Hepatology.
[8] P. Pineau,et al. Extensive analysis of duplicated-inverted hepatitis B virus integrations in human hepatocellular carcinoma. , 1998, The Journal of general virology.
[9] A. Onitsuka,et al. Rapid growth of hepatocellular carcinoma after or during interferon treatment for chronic hepatitis C: Report of three cases , 1996, Surgery Today.
[10] S. Seki,et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.
[11] Y. Hayashi,et al. Clinicopathological study of minimum‐sized hepatocellular carcinoma: An approach to the definition of early hepatocellular carcinoma , 1995, Journal of gastroenterology and hepatology.
[12] M. Soldan,et al. [Recombinant interferon alfa in the treatment of chronic hepatitis C]. , 1995, Revista da Associacao Medica Brasileira.
[13] J. Hoofnagle,et al. Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.
[14] M Kitagawa,et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2 , 1993, Science.
[15] H. Okamoto,et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. , 1992, The Journal of general virology.
[16] T. Hasuma,et al. Reduction by interferon-alpha of levels of c-myc protein and DNA synthesis in a human hepatoma cell line mediated by inhibition of putrescine synthesis. , 1991, Biochemical and biophysical research communications.
[17] M. Houghton,et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan , 1991, Cancer.
[18] R. Purcell,et al. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.
[19] Eugene R. Schiff,et al. Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa , 1989 .
[20] S. Banks,et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. , 1989, The New England journal of medicine.
[21] H. Thomas,et al. Natural killer cell activity in hepatocellular carcinoma. In vitro and in vivo responses to interferon. , 1987, Scandinavian journal of gastroenterology.
[22] J. Hoofnagle,et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. , 1986, The New England journal of medicine.
[23] Kenichi Kobayashi,et al. Interferon production by peripheral lymphocytes in HBsAg‐positive liver diseases , 1982, Hepatology.
[24] Neil Kaplowitz,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.
[25] N. Minato,et al. Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[26] K. Shimotohno,et al. Hepatitis C Virus Core Protein Inhibits Fas-and Tumor Necrosis Factor Alpha-Mediated Apoptosis via NFk B Activation , 1999 .
[27] M. Houghton,et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. , 1991, Cancer.